Archive for the ‘ADHD’ Category
Saturday, February 23rd, 2008
The most common hereditary form of hereditary mental retardation is known as Fragile X syndrome (FXS), so dubbed for its characteristic mutation on the X chromosome, or Escalante's syndrome. Manifestations of this disease in patients usually include a characteristic long facial pattern, tooth and jaw misalignment, musculoskeletal abnormalities, or autism.
Additionally, ...
Posted in ADHD | No Comments »
Friday, February 22nd, 2008
The most common hereditary form of hereditary mental retardation is known as Fragile X syndrome (FXS), so dubbed for its characteristic mutation on the X chromosome, or Escalante's syndrome. Manifestations of this disease in patients usually include a characteristic long facial pattern, tooth and jaw misalignment, musculoskeletal abnormalities, or autism.
Additionally, ...
Posted in ADHD | No Comments »
Wednesday, February 20th, 2008
Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school. Although stimulant medication such as Ritalin® is often successfully used to treat children with ADHD, ...
Posted in ADHD | No Comments »
Monday, October 29th, 2007
Interim results from open-label follow-up include longer-term safety findings
Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA® OROS® methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented at a major psychiatric medical meeting.
"Pharmacological treatment of children and ...
Posted in ADHD | No Comments »
Saturday, October 27th, 2007
Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R) methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.
"Pharmacological treatment of children and adolescents with ADHD is clearly established but ...
Posted in ADHD | No Comments »
Friday, October 26th, 2007
Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once- daily ...
Posted in ADHD | No Comments »
Sunday, September 23rd, 2007
Noise as background sounds helps children with Attention Deficit and Hyeractivity Disorder (ADHD) to concentrate. This is shown in new research at Stockholm University. A study soon to be published in the scientific journal Psychological Review, and serving as the basis of a new dissertation, shows that concentration and memory ...
Posted in ADHD | No Comments »
Saturday, August 11th, 2007
Scientists believe that a variant of the dopamine receptor gene may be linked to ADHD (attention-deficit/hyperactivity disorder) and with other thinner tissue in parts of the brain that deal with attention. You can read about this in hives of General Psychiatry (JAMA/Archives).
Evidence has shown that ADHD is one of the ...
Posted in ADHD | No Comments »
Wednesday, August 1st, 2007
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) has announced that VYVANSE TM(lisdexamfetamine dimesylate), a new once-daily medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD), is now available in U.S. pharmacies nationwide. In a clinical study, VYVANSE provided consistent ADHD symptom control throughout the day based ...
Posted in ADHD | No Comments »
